PATENT CLAIM ANALYSIS

Application Number: 16370606
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-07
Patent Classification: ["435", "455000"]

Abstract:
Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.

Claim (Index 21):
An isolated allogeneic human beta cell that is resistant to cell death in the presence human immune cells.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 99.0
- Lexical Diversity: 1.33333
- Patent Class: 435.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['11667410', '15840930', '15258887', '11407477', '15179567']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5237238159131296
- 35 USC 102 Novelty (BERT): 0.495381892258575
- Combined Prediction Score: 0.5208896235476741
- Mean Citation Score: 162.043034
- Max Citation Score: 164.33176
- Similarity Product: 105.03182548464775

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test